- Report
- March 2025
- 200 Pages
Global
From €4109EUR$4,490USD£3,570GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2552EUR$2,789USD£2,218GBP
- Report
- September 2019
- 30 Pages
China
From €2013EUR$2,200USD£1,749GBP
- Report
- November 2022
- 96 Pages
From €3157EUR$3,450USD£2,743GBP
- Report
- November 2022
- 97 Pages
North America
From €3157EUR$3,450USD£2,743GBP
- Report
- November 2022
- 100 Pages
Middle East, Africa
From €3157EUR$3,450USD£2,743GBP
- Report
- November 2022
- 107 Pages
Europe
From €3157EUR$3,450USD£2,743GBP
- Report
- November 2022
- 112 Pages
Asia Pacific
From €3157EUR$3,450USD£2,743GBP
- Report
- August 2022
- 176 Pages
Global
From €4072EUR$4,450USD£3,538GBP
- Report
- March 2024
- 257 Pages
Global
From €6863EUR$7,500USD£5,963GBP
- Report
- April 2023
- 90 Pages
India
From €4347EUR$4,750USD£3,777GBP
- Report
- April 2023
- 120 Pages
Global
From €4347EUR$4,750USD£3,777GBP
- Report
- August 2023
- 101 Pages
Global
From €3500EUR$4,097USD£3,147GBP
- Report
- July 2023
- 99 Pages
Global
From €3500EUR$4,097USD£3,147GBP
- Report
- July 2023
- 105 Pages
Global
From €3500EUR$4,097USD£3,147GBP
- Book
- November 2009
- 384 Pages
Asparaginase is a type of drug used to treat leukemia, a type of cancer. It works by breaking down the amino acid asparagine, which is essential for the growth of cancer cells. Asparaginase is used in combination with other chemotherapy drugs to treat acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). It is also used to treat non-Hodgkin's lymphoma and other types of cancer. Asparaginase is available in both injectable and oral forms. The injectable form is usually given intravenously, while the oral form is taken as a pill.
The asparaginase market is highly competitive, with several companies offering different formulations of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and Bristol-Myers Squibb. Other companies include Amgen, Teva Pharmaceuticals, and Eli Lilly. Show Less Read more
